Call Made to Speed Cell-Therapy Development.
A recently released white paper calls for updating FDA regulations around the development of cell therapies. The authors suggest changing the investigational new drug pathway exploratory trials, including easing manufacturing requirements for early studies and allowing for greater flexibility to revise protocols as studies progress.